Biosense Webster Launches Report - The Burden of Atrial Fibrillation: Understanding the Impact of the New Millennium Epidemic Across Europe
Biosense Webster EMEA, a Division of Johnson & Johnson Medical NV/SA and leader in the treatment of Atrial Fibrillation (AF) has today, during AF Association Global AF Aware Week, published a report that uncovers the growing burden of AF on patients, caregivers and healthcare systems across Europe.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20181118005008/en/
The new report is calling for greater awareness and emphasis on the scale and impact of AF which is fast becoming one of the world’s most significant health issues. The new millennium epidemic not only disrupts the quality of life for the 11 million people across Europe who suffer from AF, but also costs healthcare systems up to €3,286 million annually across European countries.2-7
AF is characterized by an irregular and often fast heart rhythm that results in uncoordinated contraction of the top two chambers of the heart. The irregular heart rhythm may cause blood clots, as blood can pool in the heart before being pumped into the brain causing an AF related stroke, a particularly debilitating form of stroke. AF is typically a progressive disease, with 1 in 5 patients progressing from paroxysmal (intermittent) AF to persistent (constant) AF in 1 year.8-10
The report highlights that by 2030 the number of people with AF is projected to increase by up to 70%,1 and that by 2050 Europe will have the greatest increase in AF patients compared to other regions globally.11 Furthermore, by 2030 the number of stroke events and medical visits is expected to increase, with 280,000-340,000 new ischemic strokes, 3.5-4 million hospitalizations for AF and 100-120 million outpatient visits expected.1
“AF is the most common heart arrhythmia and can be a debilitating disease with life-threatening complications for patients and, unfortunately, is set to become even more prevalent in Europe. The lack of awareness of the burden of AF means that it is difficult to prioritize on the health agenda despite its increasing impact on healthcare systems. The report developed by Biosense Webster serves as a welcome tool that clearly outlines the critical situation and provides a good starting point for us in the cardiology community to renew the focus on AF,” said Professor Gerhard Hindricks, Heart Center Leipzig, University of Leipzig,
“We welcome this new report which brings a much-needed focus on the burden of AF for patients and their families. We also know these prevalence figures are likely to be under-estimates of the scale of the problem, since almost 4 million people are living with undiagnosed AF. We are working towards ways to improve earlier diagnosis as this leads to better management and outcomes for AF patients and less need for high cost emergency care”, commented Trudie Lobban MBE, Founder and CEO, Arrhythmia Alliance and AF Association.
‘’Supporting loved ones and family members with AF can have a significant impact on the lives of the caregivers, who make sacrifices and devote their time and energy at the expense of their own lives and are therefore at high risk of stress. By building a full picture of the impact of AF both on patients and caregivers we will be able to concentrate our efforts and work towards helping to alleviate this burden, experienced by millions across Europe,” added Lobban.
“For over 20 years Biosense Webster has pioneered the development of AF ablation treatments and through partnering with clinicians have been able to heal the hearts of thousands of patients” explains Gabriele Fischetto, Vice President of Johnson & Johnson Cardiovascular Specialty Solutions in EMEA. “However, AF is becoming increasingly prevalent and we need urgent focus to understand the true burden of the disease, so we can work together to tackle it head on.”
A full copy of the report and supporting materials, including an infographic, is available at:
Details on AF Association Global AF Aware Week are available at: http://www.heartrhythmalliance.org/
- ENDS -
NOTES TO EDITORS
About the Johnson & Johnson Medical Devices Companies
As the world’s most comprehensive medical devices business*, we are building on a century of experience, merging science and technology, to shape the future of health and benefit even more people around the world. With our unparalleled breadth, depth and reach across surgery, orthopaedics and interventional solutions, we’re working to profoundly change the way care is delivered. We are in this for life. For more information, visit www.jnjmedicaldevices.com.
About Biosense Webster
Biosense Webster, Inc., part of Johnson & Johnson Medical Devices Companies, is a global leader in the science of diagnosing and treating heart rhythm disorders. The company partners with clinicians to develop innovative technologies that improve the quality of care for arrhythmia patients worldwide. For more information, visit www.biosensewebster.com.
*Comprising the surgery, orthopaedics, and interventional solutions businesses within the Johnson & Johnson’s Medical Devices segment
© Johnson & Johnson Medical NV/SA 2018 - 099962-181002
1. Zoni-Berisso M, Lercari F, Carazza T, Domenicucci S (2014) Epidemiology of atrial fibrillation: European perspective. Clin Epidemiol 6 213-220.
2. McBride D, Mattenklotz AM, Willich SN, Bruggenjurgen B (2009) The costs of care in atrial fibrillation and the effect of treatment modalities in Germany. Value Health 12 (2): 293-301.
3. Ball J, Carrington MJ, McMurray JJ, Stewart S (2013) Atrial fibrillation: profile and burden of an evolving epidemic in the 21st century. Int J Cardiol 167 (5): 1807-1824.
4. Cotte FE, Chaize G, Gaudin AF, Samson A, Vainchtock A et al. (2016) Burden of stroke and other cardiovascular complications in patients with atrial fibrillation hospitalized in France. Europace 18 (4): 501-507.
5. Stewart S, Murphy NF, Walker A, McGuire A, McMurray JJ (2004) Cost of an emerging epidemic: an economic analysis of atrial fibrillation in the UK. Heart 90 (3): 286-292.
6. Global Burden of Disease Collaborative Network (2016) Global Burden of Disease Study 2016 (GBD 2016) Results. Seattle, United States: Institute for Health Metrics and Evaluation (IHME), 2017. Accessed 2018-04-20. Available from http://ghdx.healthdata.org/gbd-results-tool.
7. GBD 2016 Disease and Injury Incidence and Prevalence Collaborators (2017) Global, regional, and national incidence, prevalence, and years lived with disability for 328 diseases and injuries for 195 countries, 1990-2016: a systematic analysis for the Global Burden of Disease Study 2016. Lancet 390 (10100): 1211-1259.
8. Nieuwlaat R, Prins MH, Le Heuzey JY, Vardas PE, Aliot E et al. (2008) Prognosis, disease progression, and treatment of atrial fibrillation patients during 1 year: follow-up of the Euro Heart Survey on atrial fibrillation. Eur Heart J 29 (9): 1181-1189.
9. de Vos CB, Pisters R, Nieuwlaat R, Prins MH, Tieleman RG et al. (2010) Progression from paroxysmal to persistent atrial fibrillation clinical correlates and prognosis. J Am Coll Cardiol 55 (8): 725-731.
10. Schnabel R, Pecen L, Engler D, Lucerna M, Sellal JM et al. (2018) Atrial fibrillation patterns are associated with arrhythmia progression and clinical outcomes. Heart
11. Rahman F, Kwan GF, Benjamin EJ (2014) Global epidemiology of atrial fibrillation. Nat Rev Cardiol 11 (11): 639-654.
© Johnson & Johnson Medical NV/SA 2018 - 099962-181002
+44 (0)7825 378 894
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Tilaa tiedotteet sähköpostiisi
Haluatko tietää asioista ensimmäisten joukossa? Kun tilaat mediatiedotteemme, saat ne sähköpostiisi välittömästi julkaisuhetkellä. Tilauksen voit halutessasi perua milloin tahansa.
Lue lisää julkaisijalta Business Wire
Tommy Hilfiger Calls on Social Entrepreneurs to Take on the Tommy Hilfiger Fashion Frontier Challenge21.3.2019 11:00:00 EET | Tiedote
Tommy Hilfiger, which is owned by PVH Corp. [NYSE: PVH], is pleased to announce that year two applications for the Tommy Hilfiger Fashion Frontier Challenge are now open. The global program aims to support entrepreneurial start-up and scale-up stage businesses developing solutions that promote inclusive and positive change in fashion. After a successful first year, the company is excited to continue to work on identifying opportunities that support the advancement of the fashion industry. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20190321005068/en/ The prestigious jury panel and TOMMY HILFIGER Challenge winners at the Final Event. (Photo: Business Wire) “The first chapter of this global initiative was an inspiring journey that put a spotlight on incredible ideas that could change the lives of people through a more positive and inclusive fashion landscape,” said Tommy Hilfiger. “Through the Tommy Hilfiger Fashion Frontier
Elliott Statement on Proposal to Uniper21.3.2019 10:00:00 EET | Tiedote
Elliott Advisors (UK) Limited (“Elliott”) has written to the Management Board of Uniper SE (the “Company” or “Uniper”), to formally request the convocation of an Extraordinary General Meeting (“EGM”) with the express purpose of instructing management to prepare a lawful domination agreement with the Company’s largest shareholder Fortum Oyj (“Fortum”). Elliott believes the thus far ill-defined and ambiguous nature of the relationship between Uniper and Fortum has created an unsatisfactory and unsustainable dynamic, which is detrimental to Uniper. In Elliott’s view, the status quo – operational underperformance and pervasive uncertainty – if sustained, will risk further undermining the Company’s fundamental value. Elliott believes a timely shareholder vote to advance a domination agreement may resolve the prolonged uncertainty at Uniper and clarify the relationship between the Company and Fortum, such that value can be created for the Company and all stakeholders. Elliott believes that F
Key UK SEP Patent Win for TQ Delta20.3.2019 22:03:00 EET | Tiedote
TQ Delta LLC, a technology development and licensing firm, secured a judgment on March 18 by the High Court of Justice of England and Wales immediately enjoining ZyXEL Communications UK Ltd and its Danish parent company, ZyXEL Communications A/S, from further infringement of TQ Delta's European Patent (UK) 1 453 268. TQ Delta's patent relates to Digital Subscriber Line ("DSL") technology. In an earlier judgment, handed down on March 12, the Court found that the patent was valid and essential to the operation of ADSL2 and VDSL2. In that judgment, the Court held that the ZyXEL defendants have infringed and continue to infringe the patent. The Court also found that a second patent would have also been essential and infringed but was invalid. In its judgment earlier this week, the Court also found that the ZyXEL defendants were "holding out" against taking a licence to TQ Delta's portfolio of patents relating to DSL. It granted an immediate injunction and costs against the ZyXEL defendants
Lehman Brothers Treasury Announces the Successful Auction of a Portion of its Intercompany Claim against Lehman Brothers Holdings Inc.20.3.2019 21:15:00 EET | Tiedote
In connection with its previously announced partial wind-down, Lehman Brothers Treasury Co. B.V. in liquidation (“LBT”), through its U.S. counsel Kramer Levin Naftalis & Frankel LLP, announced that its placement agent, Seaport Loan Products LLC, successfully concluded an auction of a US$10,475,844,413 portion of LBT’s US$34,548,000,000 intercompany claim (the “Intercompany Claim”) against Lehman Brothers Holdings Inc. for a total gross purchase price of US$179,472,166. The sale is expected to close during the first week of April 2019. The net proceeds of the sale (after deducting various sale-related costs and expenses), together with certain available cash, will be used to fund a final distribution to creditors of LBT who do not receive substitute notes as a result of LBT’s prior solicitation process. For more information on the partial wind-down, including information about the Intercompany Claim sale, the final cash distribution, and anticipated timelines, an Information Notice has
Susan Ochs Joins PSB as Global Head, Financial Services20.3.2019 20:34:00 EET | Tiedote
PSB, a global research-based consultancy, announced today that Susan Ochs has joined the firm as Senior Vice President and Global Head, Financial Services, effective immediately. Ochs is based in New York and is responsible for the global development of the financial services practice and will contribute to other industry practices as well. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20190320005671/en/ Susan Ochs, SVP, Global Head, Financial Services, PSB (Photo: Business Wire) “We are proud of the amazing brands we currently partner with across the financial sector,” said Mike Chuter, CEO, PSB, to whom Ochs reports. “With Susan’s combination of private and public finance expertise we’ll be able to deliver even more meaningful insights to our current and future partners. We are delighted to welcome Susan and are excited about the deep experience she brings.” Ochs has more than two decades of experience across the financial
Corsair Infrastructure Partners Announces Long Term Investments by HarbourVest Partners20.3.2019 17:35:00 EET | Tiedote
Corsair Infrastructure Partners (“CIP”), the global infrastructure investment business of Corsair Capital (“Corsair”), today announced that HarbourVest Partners (“HarbourVest”), a leading institutional investor active across multiple asset classes and geographies, has invested in three new CIP-managed funds established to deploy capital in the aviation, port, and road sectors. Earlier this year, CIP’s new funds closed on the acquisitions of shareholdings in three platform companies – the airport developer Vantage Airport Group, the Australian stevedore DP World Australia, and the Spanish toll-road operator Itínere Infraestructuras – from various selling shareholders including Gateway Infrastructure Investments, a legacy CIP-managed vehicle. The investments from HarbourVest come from a long-term pool of institutional capital dedicated to supporting infrastructure equity sponsors like CIP, and will play an important role in the execution of CIP’s growth strategies for all three platforms
Uutishuoneessa voit lukea tiedotteitamme ja muuta julkaisemaamme materiaalia. Löydät sieltä niin yhteyshenkilöidemme tiedot kuin vapaasti julkaistavissa olevia kuvia ja videoita. Uutishuoneessa voit nähdä myös sosiaalisen median sisältöjä. Kaikki STT Infossa julkaistu materiaali on vapaasti median käytettävissä.Tutustu uutishuoneeseemme